These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

938 related articles for article (PubMed ID: 33574116)

  • 1. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider.
    Najm A; Alunno A; Mariette X; Terrier B; De Marco G; Emmel J; Mason L; McGonagle DG; Machado PM
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33574116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.
    Alunno A; Najm A; Mariette X; De Marco G; Emmel J; Mason L; McGonagle DG; Machado PM
    Ann Rheum Dis; 2021 Jun; 80(6):803-815. PubMed ID: 33589438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
    Havervall S; Ng H; Jernbom Falk A; Greilert-Norin N; Månberg A; Marking U; Laurén I; Gabrielsson L; Salomonsson AC; Aguilera K; Kihlgren M; Månsson M; Rosell A; Hellström C; Andersson E; Olofsson J; Skoglund L; Yousef J; Pin E; Lord M; Åberg M; Hedhammar M; Tegel H; Dönnes P; Phillipson M; Nilsson P; Klingström J; Mangsbo S; Hober S; Thålin C
    J Intern Med; 2022 Jan; 291(1):72-80. PubMed ID: 34459525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Analysis of Human Memory T-Cell Response According to the Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Kang CK; Kim M; Lee S; Kim G; Choe PG; Park WB; Kim NJ; Lee CH; Kim IS; Jung K; Lee DS; Shin HM; Kim HR; Oh MD
    J Infect Dis; 2021 Jul; 224(1):39-48. PubMed ID: 33755725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperinflammation and Immune Response Generation in COVID-19.
    Mishra KP; Singh AK; Singh SB
    Neuroimmunomodulation; 2020; 27(2):80-86. PubMed ID: 33341814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay of Antibody and Cytokine Production Reveals CXCL13 as a Potential Novel Biomarker of Lethal SARS-CoV-2 Infection.
    Horspool AM; Kieffer T; Russ BP; DeJong MA; Wolf MA; Karakiozis JM; Hickey BJ; Fagone P; Tacker DH; Bevere JR; Martinez I; Barbier M; Perrotta PL; Damron FH
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects.
    Zheng J; Deng Y; Zhao Z; Mao B; Lu M; Lin Y; Huang A
    Cell Mol Immunol; 2022 Feb; 19(2):150-157. PubMed ID: 34645940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism.
    Policard M; Jain S; Rego S; Dakshanamurthy S
    Virus Res; 2021 Aug; 301():198464. PubMed ID: 34058265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Cytokine and Chemokine Dysregulation in Hospitalized Children With Acute Coronavirus Disease 2019 and Multisystem Inflammatory Syndrome With Similar Levels of Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 Shedding.
    Peart Akindele N; Kouo T; Karaba AH; Gordon O; Fenstermacher KZJ; Beaudry J; Rubens JH; Atik CC; Zhou W; Ji H; Tao X; Vaidya D; Mostafa H; Caturegli P; Blair PW; Sauer L; Cox AL; Persaud D
    J Infect Dis; 2021 Aug; 224(4):606-615. PubMed ID: 34398245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.
    Sasson JM; Campo JJ; Carpenter RM; Young MK; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Teng AA; Pablo JV; Liang X; Yee A; Petri WA; Camerini D
    mBio; 2021 Jun; 12(3):e0122921. PubMed ID: 34182775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity.
    Lin J; Law R; Korosec CS; Zhou C; Koh WH; Ghaemi MS; Samaan P; Ooi HK; Matveev V; Yue F; Gingras AC; Estacio A; Buchholz M; Cheatley PL; Mohammadi A; Kaul R; Pavinski K; Mubareka S; McGeer AJ; Leis JA; Heffernan JM; Ostrowski M
    J Virol; 2022 Jul; 96(13):e0050922. PubMed ID: 35699447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral loads, lymphocyte subsets and cytokines in asymptomatic, mildly and critical symptomatic patients with SARS-CoV-2 infection: a retrospective study.
    Yin SW; Zhou Z; Wang JL; Deng YF; Jing H; Qiu Y
    Virol J; 2021 Jun; 18(1):126. PubMed ID: 34118952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome.
    Weiskopf D; Schmitz KS; Raadsen MP; Grifoni A; Okba NMA; Endeman H; van den Akker JPC; Molenkamp R; Koopmans MPG; van Gorp ECM; Haagmans BL; de Swart RL; Sette A; de Vries RD
    Sci Immunol; 2020 Jun; 5(48):. PubMed ID: 32591408
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 47.